SA
BIO icon

Shilanski & Associates’s Bio-Rad Laboratories Class A BIO Stock Holding History

Shilanski & Associates’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,225
Closed -$926K – 126
2021
Q4 		$926K Buy
+1,225
New +$917K 0.39% 63

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Shilanski & Associates's BIO Position: Q1 2022 in Review

Shilanski & Associates sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 1,225 shares — an estimated $926K sold.

Shilanski & Associates first reported a position in BIO in Q4 2021 and held it in 1 quarter. The position peaked at $926K in Q4 2021. 514 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

  • Shilanski & Associates reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
  • Shilanski & Associates sold 1,225 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $926K.
  • Shilanski & Associates first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and held it in 1 quarter.
  • Shilanski & Associates's Bio-Rad Laboratories Class A position peaked at $926K in Q4 2021.
  • 514 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Shilanski & Associates's 13F filing for Q1 2022, filed 20 Apr 2022.